Display options
Cite
Arnett AL, Garikipati D, Wang Z, et al. Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector. Front Microbiol. 2011;2:220doi: 10.3389/fmicb.2011.00220.
Arnett, A. L., Garikipati, D., Wang, Z., Tapscott, S., & Chamberlain, J. S. (2011). Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector. Frontiers in microbiology, 2220. https://doi.org/10.3389/fmicb.2011.00220
Arnett, Andrea L H, et al. "Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector." Frontiers in microbiology vol. 2 (2011): 220. doi: https://doi.org/10.3389/fmicb.2011.00220
Arnett AL, Garikipati D, Wang Z, Tapscott S, Chamberlain JS. Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector. Front Microbiol. 2011 Nov 03;2:220. doi: 10.3389/fmicb.2011.00220. eCollection 2011. PMID: 22065964; PMCID: PMC3207220.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2011 Nov 03;2:220. doi: 10.3389/fmicb.2011.00220. eCollection 2011.

Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector.

Frontiers in microbiology

Andrea L H Arnett, Dilip Garikipati, Zejing Wang, Stephen Tapscott, Jeffrey S Chamberlain

Affiliations

  1. Medical Scientist Training Program, University of Washington School of Medicine Seattle, WA, USA.

PMID: 22065964 PMCID: PMC3207220 DOI: 10.3389/fmicb.2011.00220

Abstract

Recombinant adeno-associated viral (rAAV) vectors promote long-term gene transfer in many animal species. Significant effort has focused on the evaluation of rAAV delivery and the immune response in both murine and canine models of neuromuscular disease. However, canines provided for research purposes are routinely vaccinated against canine parvovirus (CPV). rAAV and CPV possess significant homology and are both parvoviruses. Thus, any immune response generated to CPV vaccination has the potential to cross-react with rAAV vectors. In this study, we investigated the immune response to rAAV6 delivery in a cohort of CPV-vaccinated canines and evaluated multiple vaccination regimens in a mouse model of CPV-vaccination. We show that CPV-vaccination stimulates production of neutralizing antibodies with minimal cross-reactivity to rAAV6. In addition, no significant differences were observed in the magnitude of the rAAV6-directed immune response between CPV-vaccinated animals and controls. Moreover, CPV-vaccination did not inhibit rAAV6-mediated transduction. We also evaluated the immune response to early rAAV6-vaccination in neonatal mice. The influence of maternal hormones and cytokines leads to a relatively permissive state in the neonate. We hypothesized that immaturity of the immune system would permit induction of tolerance to rAAV6 when delivered during the neonatal period. Mice were vaccinated with rAAV6 at 1 or 5 days of age, and subsequently challenged with rAAV6 exposure during adulthood via two sequential IM injections, 1 month apart. All vaccinated animals generated a significant neutralizing antibody response to rAAV6-vaccination that was enhanced following IM injection in adulthood. Taken together, these data demonstrate that the immune response raised against rAAV6 is distinct from that which is elicited by the standard parvoviral vaccines and is sufficient to prevent stable tolerization in neonatal mice.

Keywords: AAV; canine; immune response; immunity; muscle; parvovirus; tolerance; vaccination

References

  1. Mol Ther. 2010 Jun;18(6):1165-72 - PubMed
  2. Blood. 2002 Apr 15;99(8):2670-6 - PubMed
  3. Mol Ther. 2008 Jul;16(7):1189-99 - PubMed
  4. Hum Gene Ther. 2007 Jan;18(1):18-26 - PubMed
  5. Curr Gene Ther. 2007 Oct;7(5):316-24 - PubMed
  6. J Gene Med. 2003 Nov;5(11):941-50 - PubMed
  7. Nat Med. 2004 Aug;10(8):828-34 - PubMed
  8. Gene Ther. 2008 Jan;15(1):54-60 - PubMed
  9. J Infect Dis. 2009 Feb 1;199(3):381-90 - PubMed
  10. Mol Ther. 2009 Aug;17(8):1427-33 - PubMed
  11. Mol Ther. 2004 Oct;10(4):671-8 - PubMed
  12. AIDS. 2006 Feb 28;20(4):483-94 - PubMed
  13. Mol Ther. 2009 Jan;17(1):73-80 - PubMed
  14. Hum Gene Ther. 2007 Apr;18(4):344-54 - PubMed
  15. Gene Ther. 2008 Jun;15(11):808-16 - PubMed
  16. J Virol. 2001 Jul;75(14):6615-24 - PubMed
  17. Gene Ther. 2006 Sep;13(17):1300-8 - PubMed
  18. Proc Natl Acad Sci U S A. 1982 Mar;79(6):2077-81 - PubMed
  19. Blood. 2009 Sep 3;114(10):2077-86 - PubMed
  20. J Immunol. 2001 Jan 15;166(2):918-25 - PubMed
  21. Pediatr Res. 2002 Jul;52(1):95-104 - PubMed
  22. Mol Ther. 2000 Oct;2(4):374-80 - PubMed
  23. Mol Ther. 2004 Aug;10(2):302-17 - PubMed
  24. Gene Ther. 2009 Mar;16(3):311-9 - PubMed
  25. Ann Neurol. 2010 Nov;68(5):629-38 - PubMed
  26. Mol Ther. 2010 Jul;18(7):1318-29 - PubMed
  27. Curr Opin Genet Dev. 2009 Jun;19(3):290-7 - PubMed
  28. Mol Ther. 2007 Sep;15(9):1677-85 - PubMed
  29. Vaccine. 2009 Jan 22;27(4):491-504 - PubMed
  30. Hum Genet. 2006 Jul;119(6):571-603 - PubMed
  31. ILAR J. 2009;50(2):187-98 - PubMed
  32. Curr Opin Immunol. 2010 Oct;22(5):623-30 - PubMed
  33. Mol Ther. 2010 Dec;18(12):2146-54 - PubMed
  34. Gene Ther. 2007 Sep;14(17):1249-60 - PubMed
  35. Gene Ther. 2010 Mar;17(3):295-304 - PubMed
  36. Mol Ther. 2007 Feb;15(2):229-41 - PubMed
  37. Vet Immunol Immunopathol. 2002 Sep 10;87(3-4):207-13 - PubMed
  38. Mucosal Immunol. 2010 Jul;3(4):326-33 - PubMed
  39. Nat Med. 2006 Jul;12(7):787-9 - PubMed
  40. Nat Genet. 2000 Mar;24(3):257-61 - PubMed
  41. Curr Gene Ther. 2005 Jun;5(3):323-31 - PubMed
  42. Mol Ther. 2003 Jun;7(6):839-50 - PubMed
  43. J Virol. 2000 Feb;74(3):1524-32 - PubMed
  44. Mol Ther. 2008 Jun;16(6):1073-80 - PubMed
  45. Mol Ther. 2010 Mar;18(3):617-24 - PubMed
  46. Nat Med. 2006 Mar;12(3):342-7 - PubMed
  47. Mol Ther. 2007 Jun;15(6):1160-6 - PubMed
  48. J Comp Pathol. 2007 Jul;137 Suppl 1:S27-31 - PubMed
  49. Gene Ther. 2004 Oct;11 Suppl 1:S109-21 - PubMed

Publication Types

Grant support